ℹ️
🇬🇧
Search
Search for publications relevant for "INCB050465"
INCB050465
Publication
Class
Person
Publication
Programmes
publication
Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3Kδ inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202)
2021 |
Faculty of Medicine in Hradec Králové
